Mammalian target of rapamycin has recently been recognised as an important and attractive target for anti-cancer therapy (Boulay et al, 2004; Bianco et al, 2006; Johnston, 2006; Antonarakis et al, 2010; Sparks and Guertin, 2010). The gene discussed is MTOR; the disease is cancer.